Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer

This study tests combining an immunotherapy drug (sintilimab) with chemotherapy and radiation for patients with advanced pancreatic cancer that cannot be surgically removed. Researchers hope this combination can improve outcomes better than standard treatment alone. **You may be eligible if...** - You have been diagnosed with locally advanced pancreatic cancer that cannot be surgically removed, confirmed by tissue biopsy - You have not yet received any cancer treatment for this condition - You are in good overall health and have a life expectancy of more than 3 months - Your blood counts and organ function are within acceptable ranges **You may NOT be eligible if...** - You were diagnosed with another cancer in the past 3 years - You are currently in another clinical trial - You have active autoimmune conditions or are on immune-suppressing medications - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.